• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RVA
Click for more information
0.00% 0.0¢

REVA MEDICAL, INC - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
RVA REVA Completes Clinical Enrollment MilestonePRICE SENSITIVE01/10/15
RVA Regina Groves Appointed as Chief Executive OfficerPRICE SENSITIVE21/08/15
RVA Half Yearly Report and Accounts (Appendix 4D)PRICE SENSITIVE11/08/15
RVA Notice of Briefing Call06/08/15
RVA Appendix 4C - quarterlyPRICE SENSITIVE31/07/15
RVA Appendix 3B10/07/15
RVA Updated Insider Trading Policy16/06/15
RVA Change of Director's Interest Notice10/06/15
RVA Change of Director's Interest Notice09/06/15
RVA Appendix 3B04/06/15
RVA Change of Director's Interest Notice03/06/15
RVA Change of Director's Interest Notice03/06/15
RVA Change of Director's Interest Notice03/06/15
RVA Change of Director's Interest Notice03/06/15
RVA Change of Director's Interest Notice03/06/15
RVA Change of Director's Interest Notice03/06/15
RVA Change of Director's Interest Notice03/06/15
RVA AGM Results28/05/15
RVA AGM Presentation28/05/15
RVA Initial Clinical Results for Fantom ScaffoldPRICE SENSITIVE22/05/15
RVA REVA to Present at EuroPCR Conference18/05/15
RVA FANTOM II Clinical Trial Expanded to AustraliaPRICE SENSITIVE15/05/15
RVA Quarterly Report on Form 10-Q & AGM Dial-In Details15/05/15
RVA REVA Undertakes Search for Chief Executive OfficerPRICE SENSITIVE14/05/15
RVA Proxy Statement for 2015 AGM01/05/15
RVA Appendix 4C - quarterlyPRICE SENSITIVE30/04/15
RVA Fantom II Clinical Trial Expanded to EuropePRICE SENSITIVE23/04/15
RVA Initial Director's Interest Notice01/04/15
RVA Annual Report on Form 10-K31/03/15
RVA Form S-8 Filed with SEC31/03/15
RVA Scott Huennekens Appointed to Board of Directors26/03/15
RVA Notice of Briefing Call24/03/15
RVA Appendix 3B24/03/15
RVA Initiation of FANTOM II Clinical Trial & Live Implant at ACCPRICE SENSITIVE16/03/15
RVA Preliminary Final ReportPRICE SENSITIVE27/02/15
RVA Presentations at CRT Conference24/02/15
RVA Initial Director's Interest Notice05/02/15
RVA Appendix 4C - quarterlyPRICE SENSITIVE30/01/15
RVA Dr. Ross Breckenridge Appointed to Board of Directors29/01/15
RVA Presentation at J.P. Morgan Healthcare Conference16/01/15
RVA REVA to Present at J.P. Morgan Healthcare Conference12/01/15
RVA Change of Auditors22/12/14
RVA Change in Registered Office05/12/14
RVA REVA Implants First Patients with Fantom ScaffoldPRICE SENSITIVE04/12/14
RVA Change of Director's Interest Notice26/11/14
RVA REVA Closes Financing21/11/14
RVA Appendix 3B14/11/14
RVA Quarterly Report on Form 10-Q07/11/14
RVA Notice of Briefing Call05/11/14
RVA Results of Special Meeting31/10/14
RVA Appendix 4C - quarterlyPRICE SENSITIVE31/10/14
RVA Prospectus for Offering of Convertible Notes and OptionsPRICE SENSITIVE24/10/14
RVA Details for Special Meeting of Stockholders23/10/14
RVA Appendix 3B22/10/14
RVA Update to Proxy Statement for 2014 Special Meeting16/10/14
RVA Proxy Statement for 2014 Special Meeting of Stockholders15/10/14
RVA Appendix 3B30/09/14
RVA Notice of Company Update Call26/09/14
RVA Goldman Sachs and Senrigan to Provide FinancingPRICE SENSITIVE26/09/14
RVA Presentation at TCT 2014 Conference17/09/14
RVA Change to Company's Bylaws15/09/14
RVA Half Yearly Report and Accounts (Appendix 4D)PRICE SENSITIVE08/08/14
RVA Notice of Briefing Call06/08/14
RVA Chairman's Letter to Stockholders01/08/14
RVA Appendix 4C - quarterlyPRICE SENSITIVE31/07/14
RVA Final Director's Interest Notice30/07/14
RVA Presentation at Bioresorbable Vascular Scaffold Conference25/07/14
RVA Board Member James Schiro Resigns for Health Reasons25/07/14
RVA Presentation at Wells Fargo Healthcare Conference17/06/14
RVASymposium Presentations at PCR22/05/14
RVAAppendix 3B15/05/14
RVAChange of Director's Interest Notice15/05/14
RVAChange of Director's Interest Notice15/05/14
RVAChange of Director's Interest Notice14/05/14
RVAChange of Director's Interest Notice14/05/14
RVAChange of Director's Interest Notice14/05/14
RVAAGM Results13/05/14
RVAAGM Presentation13/05/14
RVAQuarterly Report on Form 10-Q09/05/14
RVAAGM Dial-In Details06/05/14
RVAAppendix 4C - quarterlyPRICE SENSITIVE30/04/14
RVAProxy Statement for 2014 AGM & Operations Update Call03/04/14
RVANotice of Company Update Call01/04/14
RVAREVA to Focus on FANTOM ScaffoldPRICE SENSITIVE27/03/14
RVAPresentations at SIR & Polymers and Plastics Conferences25/03/14
RVAAnnual Report on Form 10-K18/03/14
RVAForm S-8 Filed with SEC18/03/14
RVAPreliminary Final ReportPRICE SENSITIVE27/02/14
RVANotice of Briefing Call and Cowen HC Conference Presentation24/02/14
RVAPresentation at CRT Conference24/02/14
RVAREVA Hires VP General Counsel11/02/14
RVAAppendix 3B31/01/14
RVAAppendix 4C - quarterlyPRICE SENSITIVE31/01/14
RVAAppendix 3B16/01/14
RVAClinical Enrollment Completion & JP Morgan Presentation14/01/14
RVAChange of Director's Interest Notice20/12/13
RVAChange of Director's Interest Notice16/12/13
RVAChange of Director's Interest Notice11/12/13
RVAAppendix 3B21/11/13
RVAQuarterly Report on Form 10-Q08/11/13
RVA REVA Completes Clinical Enrollment Milestone
01/10/15PRICE SENSITIVE
RVA Regina Groves Appointed as Chief Executive Officer
21/08/15PRICE SENSITIVE
RVA Half Yearly Report and Accounts (Appendix 4D)
11/08/15PRICE SENSITIVE
RVA Notice of Briefing Call
06/08/15
RVA Appendix 4C - quarterly
31/07/15PRICE SENSITIVE
RVA Appendix 3B
10/07/15
RVA Updated Insider Trading Policy
16/06/15
RVA Change of Director's Interest Notice
10/06/15
RVA Change of Director's Interest Notice
09/06/15
RVA Appendix 3B
04/06/15
RVA Change of Director's Interest Notice
03/06/15
RVA Change of Director's Interest Notice
03/06/15
RVA Change of Director's Interest Notice
03/06/15
RVA Change of Director's Interest Notice
03/06/15
RVA Change of Director's Interest Notice
03/06/15
RVA Change of Director's Interest Notice
03/06/15
RVA Change of Director's Interest Notice
03/06/15
RVA AGM Results
28/05/15
RVA AGM Presentation
28/05/15
RVA Initial Clinical Results for Fantom Scaffold
22/05/15PRICE SENSITIVE
RVA REVA to Present at EuroPCR Conference
18/05/15
RVA FANTOM II Clinical Trial Expanded to Australia
15/05/15PRICE SENSITIVE
RVA Quarterly Report on Form 10-Q & AGM Dial-In Details
15/05/15
RVA REVA Undertakes Search for Chief Executive Officer
14/05/15PRICE SENSITIVE
RVA Proxy Statement for 2015 AGM
01/05/15
RVA Appendix 4C - quarterly
30/04/15PRICE SENSITIVE
RVA Fantom II Clinical Trial Expanded to Europe
23/04/15PRICE SENSITIVE
RVA Initial Director's Interest Notice
01/04/15
RVA Annual Report on Form 10-K
31/03/15
RVA Form S-8 Filed with SEC
31/03/15
RVA Scott Huennekens Appointed to Board of Directors
26/03/15
RVA Notice of Briefing Call
24/03/15
RVA Appendix 3B
24/03/15
RVA Initiation of FANTOM II Clinical Trial & Live Implant at ACC
16/03/15PRICE SENSITIVE
RVA Preliminary Final Report
27/02/15PRICE SENSITIVE
RVA Presentations at CRT Conference
24/02/15
RVA Initial Director's Interest Notice
05/02/15
RVA Appendix 4C - quarterly
30/01/15PRICE SENSITIVE
RVA Dr. Ross Breckenridge Appointed to Board of Directors
29/01/15
RVA Presentation at J.P. Morgan Healthcare Conference
16/01/15
RVA REVA to Present at J.P. Morgan Healthcare Conference
12/01/15
RVA Change of Auditors
22/12/14
RVA Change in Registered Office
05/12/14
RVA REVA Implants First Patients with Fantom Scaffold
04/12/14PRICE SENSITIVE
RVA Change of Director's Interest Notice
26/11/14
RVA REVA Closes Financing
21/11/14
RVA Appendix 3B
14/11/14
RVA Quarterly Report on Form 10-Q
07/11/14
RVA Notice of Briefing Call
05/11/14
RVA Results of Special Meeting
31/10/14
RVA Appendix 4C - quarterly
31/10/14PRICE SENSITIVE
RVA Prospectus for Offering of Convertible Notes and Options
24/10/14PRICE SENSITIVE
RVA Details for Special Meeting of Stockholders
23/10/14
RVA Appendix 3B
22/10/14
RVA Update to Proxy Statement for 2014 Special Meeting
16/10/14
RVA Proxy Statement for 2014 Special Meeting of Stockholders
15/10/14
RVA Appendix 3B
30/09/14
RVA Notice of Company Update Call
26/09/14
RVA Goldman Sachs and Senrigan to Provide Financing
26/09/14PRICE SENSITIVE
RVA Presentation at TCT 2014 Conference
17/09/14
RVA Change to Company's Bylaws
15/09/14
RVA Half Yearly Report and Accounts (Appendix 4D)
08/08/14PRICE SENSITIVE
RVA Notice of Briefing Call
06/08/14
RVA Chairman's Letter to Stockholders
01/08/14
RVA Appendix 4C - quarterly
31/07/14PRICE SENSITIVE
RVA Final Director's Interest Notice
30/07/14
RVA Presentation at Bioresorbable Vascular Scaffold Conference
25/07/14
RVA Board Member James Schiro Resigns for Health Reasons
25/07/14
RVA Presentation at Wells Fargo Healthcare Conference
17/06/14
RVASymposium Presentations at PCR
22/05/14
RVAAppendix 3B
15/05/14
RVAChange of Director's Interest Notice
15/05/14
RVAChange of Director's Interest Notice
15/05/14
RVAChange of Director's Interest Notice
14/05/14
RVAChange of Director's Interest Notice
14/05/14
RVAChange of Director's Interest Notice
14/05/14
RVAAGM Results
13/05/14
RVAAGM Presentation
13/05/14
RVAQuarterly Report on Form 10-Q
09/05/14
RVAAGM Dial-In Details
06/05/14
RVAAppendix 4C - quarterly
30/04/14PRICE SENSITIVE
RVAProxy Statement for 2014 AGM & Operations Update Call
03/04/14
RVANotice of Company Update Call
01/04/14
RVAREVA to Focus on FANTOM Scaffold
27/03/14PRICE SENSITIVE
RVAPresentations at SIR & Polymers and Plastics Conferences
25/03/14
RVAAnnual Report on Form 10-K
18/03/14
RVAForm S-8 Filed with SEC
18/03/14
RVAPreliminary Final Report
27/02/14PRICE SENSITIVE
RVANotice of Briefing Call and Cowen HC Conference Presentation
24/02/14
RVAPresentation at CRT Conference
24/02/14
RVAREVA Hires VP General Counsel
11/02/14
RVAAppendix 3B
31/01/14
RVAAppendix 4C - quarterly
31/01/14PRICE SENSITIVE
RVAAppendix 3B
16/01/14
RVAClinical Enrollment Completion & JP Morgan Presentation
14/01/14
RVAChange of Director's Interest Notice
20/12/13
RVAChange of Director's Interest Notice
16/12/13
RVAChange of Director's Interest Notice
11/12/13
RVAAppendix 3B
21/11/13
RVAQuarterly Report on Form 10-Q
08/11/13
refresh Created with Sketch. REFRESH
 

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Chaos reigns markets – so let's take stock of where we're at ahead of December For many people, it feels like the world has been getting crazier each year since 2020 (or 2016.) It's likely to continue
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.